SFT-006

SFT-006 is an inhaled pharmaceutical formulation currently in early-stage development by invoX Pharma for the treatment of chronic obstructive pulmonary disease (COPD). The drug is administered using the Softhaler® technology, a proprietary, breath-actuated dry powder inhaler (DPI) platform designed to deliver medication efficiently and consistently to the lower respiratory tract. As of early 2024, SFT-006 is categorized in the preclinical or early development phase. While the specific molecular target and mechanism of action have not been publicly disclosed, the asset is part of a broader respiratory pipeline leveraging the Softhaler® platform to optimize drug delivery for pulmonary diseases.